Information Library
Results for: Case Studies - Central Nervous System
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
Asia-Pacific Expertise
May 11, 2011
Quintiles' experience and flexibility to understand cultural and communication differences across Asia Pacific provided an integrated solution which exceeded recruitment targets. -
Bypassing Barriers - Refractory Partial Epilepsy
February 2, 2011
Despite a difficult and limited patient population, Quintiles randomized 388 patients (13 over target) 10 weeks ahead of schedule. -
Parkinson's Disease - Ambitious Recruitment
February 1, 2011
Quintiles provided project management, clinical monitoring, and more for a study of a drug for patients with early stage idiopathic Parkinson’s disease. -
Epilepsy - Refining Recruitment
February 1, 2011
Quintiles provided clinical monitoring and project management for a randomized, double-blind, parallel-group, placebo and comparator controlled multicenter study of Drug X in patients with epilepsy. -
Scanning for Promise
September 15, 2010
Learn how healthy volunteers and Alzheimer’s patients were successfully recruited within the required six-month time frame. -
Anticipating the Challenge
March 3, 2010
Extensive experience and expertise in Alzheimer's Disease accelerated outcomes in multi-country Phase II study. -
Advancing Innovation
March 3, 2010
Prescreening and safety measures simplified a Phase II study of a four-dose vaccine that required multiple rating scales. -
Alzheimer's Inroads
March 3, 2010
A global, multi-site Phase III trial required a large number of patients with a specific number of sites and patients at each site. -
Global Reach Leads to CNS Recruitment Speed
March 27, 2009
Quintiles CRO truly has global reach; A customer wanted to recruit 220 patients within 14 months at 25 US sites. Quintiles decreased enrollment time to just 8 months -
Alzheimer's Disease
March 27, 2009
Quintiles worked with a client to help determine the safety and tolerability of drug x for Alzheimer's patients
Page 1 of 1 (10 results)